ORS § 442.837

Current through 2024 Regular Session legislation
Section 442.837 - Oregon Patient Safety Reporting Program
(1) The Oregon Patient Safety Reporting Program is created in the Oregon Patient Safety Commission to establish a serious adverse event reporting system to learn from adverse events. The program shall include, but is not limited to:
(a) Reporting by participants, in a timely manner and in the form determined by the Oregon Patient Safety Commission Board of Directors established in ORS 442.830, of the following:
(A) Serious adverse events;
(B) Systems and practices designed to learn from and prevent adverse events, which may include:
(i) Event investigations and analyses of adverse events;
(ii) Action plans developed and implemented to prevent similar adverse events;
(iii) Monitoring the effectiveness of patient safety or quality improvement efforts over time; and
(iv) Identifying and addressing the role of health equity in adverse events; and
(C) Patient safety plans establishing procedures and protocols.
(b) Analyzing information reported under this subsection to develop and disseminate information to improve the quality of care with respect to patient safety. This information shall be made available to participants and shall include but is not limited to recommendations regarding:
(A) Systems and practices to support patient safety;
(B) Quality improvement techniques; and
(C) Best patient safety practices.
(c) Providing technical assistance to participants.
(d) Providing aggregate, deidentified information to the public on systems and practices participants have in place to learn from and prevent adverse events.
(e) Creating incentives to improve and reward participation.
(f) Distributing written reports using aggregate, deidentified data from the program to describe statewide adverse event reporting and maintaining a website to facilitate public access to reports, as well as a list of names of participants. The reports shall include but are not limited to:
(A) The types and frequencies of reported adverse events;
(B) Yearly reported adverse event totals;
(C) Demographics of patients involved in adverse events, including but not limited to race, gender, age, disability and ethnicity;
(D) A summary of the analyses and recommendations described in paragraph (b) of this subsection; and
(E) Appropriate consumer information regarding prevention of serious adverse events.
(2) Participation in the program is voluntary. The following entities are eligible to participate:
(a) Hospitals as defined in ORS 442.015;
(b) Long term care facilities as defined in ORS 442.015;
(c) Pharmacies licensed under ORS chapter 689;
(d) Ambulatory surgical centers as defined in ORS 442.015;
(e) Outpatient renal dialysis facilities as defined in ORS 442.015;
(f) Freestanding birthing centers as defined in ORS 442.015;
(g) Independent professional health care societies or associations; and
(h) Extended stay centers licensed under ORS 441.026.
(3) Reports or other information developed and disseminated by the program may not contain or reveal the name of or other identifiable information with respect to a particular participant providing information to the commission for the purposes of ORS 442.819 to 442.851, or to any individual identified in the report or information, and upon whose patient safety data, patient safety activities and reports the commission has relied in developing and disseminating information pursuant to this section.
(4) After a serious adverse event occurs, a participant must notify, in a timely manner, each patient served by the participant who is affected by the event. Notice provided under this subsection may not be construed as an admission of liability in a civil action.
(5) The commission may collaborate with organizations and providers across the continuum of health care, including but not limited to providers of ambulatory health care, on patient safety initiatives.

ORS 442.837

Amended by 2023 Ch. 89,§ 5, eff. 1/1/2024.
Amended by 2018 Ch. 50, § 8, eff. 4/3/2018, op. 1/1/2019.
2003 c. 686, § 4; 2009 c. 436, § 5; 2011 c. 30, § 4

See note under 442.819.